L-DOS47 is currently being clinically evaluated in two clinical studies, in the United States and Poland and, as a treatment for certain patients with non-small cell lung cancer (“NSCLC”).

LDOS001 is a Phase I, open-label, dose escalation study being conducted in the United States at three centers: The University of Texas, M.D. Anderson Cancer Centre, Penn State Milton S. Hershey Medical Center; and University Hospitals Case Medical Center. The primary objective of the study is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed/carboplatin. The study will also evaluate the potential clinical benefit of L-DOS47 with this combination. (ClinicalTrials.gov Identifier: NCT02309892)

LDOS002 is an open-label Phase I/II clinical study evaluating the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC. The study is being conducted at five Polish centers: The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, the Military Medical Institute, the National Tuberculosis and Lung Diseases Research Institute, the Mazovian Center of Pulmonary Diseases and Tuberculosis in Otwock and at the Med. Polonia Hospital Poznan. (ClinicalTrials.gov Identifier: NCT02340208)

Find out more: https://clinicaltrials.gov